Literature DB >> 11114115

Time-resolved fluorometry in end-point and real-time PCR quantification of nucleic acids.

J Nurmi1, H Lilja, A Ylikoski.   

Abstract

Two time-resolved fluorescence-based methods for nucleic acid quantification are described and their results are compared. Both methods use an exogenous internal standard to eliminate errors arising from different steps of the assay. The first method is a competitive end-point assay, where the standard competes for the same primers with the actual target sequence, prostate-specific antigen (PSA) cDNA. The standard and target are quantified in a dual-label plate hybridization with lanthanide-labelled probes after a fixed number of PCR cycles. The second method is based on real-time monitoring of PCR and on the use of a novel homogeneous signal generation principle that relies on the use of a 5'-->3' exonucleolytic DNA polymerase and a probe labelled with an environment sensitive, stable and fluorescent lanthanide chelate. In this assay, a non-competitive, exogenous internal standard is used. Both assays have a wide linear range (50-5 x 10(6) and 10-5 x 10(7) input PSA cDNA molecules for the end-point and real-time assays, respectively) and there is a strong correlation between the results obtained with the two assays (r = 1.0). Being somewhat faster to perform, the real-time format is better suited for assays that require high throughput. Copyright 2000 John Wiley & -Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114115     DOI: 10.1002/1522-7243(200011/12)15:6<381::AID-BIO623>3.0.CO;2-3

Source DB:  PubMed          Journal:  Luminescence        ISSN: 1522-7235            Impact factor:   2.464


  7 in total

1.  Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Authors:  Pauliina Helo; Angel M Cronin; Daniel C Danila; Sven Wenske; Rita Gonzalez-Espinoza; Aseem Anand; Michael Koscuiszka; Riina-Minna Väänänen; Kim Pettersson; Felix K-H Chun; Thomas Steuber; Hartwig Huland; Bertrand D Guillonneau; James A Eastham; Peter T Scardino; Martin Fleisher; Howard I Scher; Hans Lilja
Journal:  Clin Chem       Date:  2009-02-20       Impact factor: 8.327

2.  Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.

Authors:  Mesude Bicak; Xing Wang; Xiaoni Gao; Xing Xu; Riina-Minna Väänänen; Pekka Taimen; Hans Lilja; Kim Pettersson; Robert J Klein
Journal:  Hum Mol Genet       Date:  2020-06-27       Impact factor: 6.150

3.  Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Leni Kauko; Pauliina Helo; Henna Kekki; Angel M Cronin; Andrew J Vickers; Martti Nurmi; Kalle Alanen; Anders Bjartell; Kim Pettersson
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

4.  Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Angel Cronin; Leni Kauko; Maria Rissanen; Otto Kauko; Henna Kekki; Siina Vidbäck; Martti Nurmi; Kalle Alanen; Kim Pettersson
Journal:  Clin Biochem       Date:  2013-02-04       Impact factor: 3.281

5.  Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.

Authors:  Riina-Minna Väänänen; Natalia Tong Ochoa; Peter J Boström; Pekka Taimen; Kim Pettersson
Journal:  BMC Urol       Date:  2015-08-21       Impact factor: 2.264

6.  Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.

Authors:  Saeid Alinezhad; Riina-Minna Väänänen; Natalia Tong Ochoa; Emily A Vertosick; Anders Bjartell; Peter J Boström; Pekka Taimen; Kim Pettersson
Journal:  BMC Urol       Date:  2016-02-29       Impact factor: 2.264

7.  Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Authors:  Saeid Alinezhad; Riina-Minna Väänänen; Jesse Mattsson; Yifeng Li; Terhi Tallgrén; Natalia Tong Ochoa; Anders Bjartell; Malin Åkerfelt; Pekka Taimen; Peter J Boström; Kim Pettersson; Matthias Nees
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.